Key Takeaways
- The U.S. Food and Drug Administration (FDA) has granted priority review for Merck's (MRK) Keytruda and Pfizer's (PFE) PADCEV combination therapy for cisplatin-ineligible muscle-invasive bladder cancer (MIBC), with trial data showing a 60% reduction in event-free survival events and a 50% reduction in the risk of death.
- Ukrainian President Volodymyr Zelenskyy and NATO Secretary General Mark Rutte discussed a US peace proposal for Ukraine, which reportedly entails "painful concessions" from Kyiv, including territorial cessions and military limitations.
- LiveSquawk released its Market Talk Weekly Review, providing a comprehensive overview of recent market developments and their implications.
FDA Accelerates Review for Keytruda-PADCEV Bladder Cancer Combination
The U.S. Food and Drug Administration (FDA) has granted priority review status to two supplemental Biologics License Applications (sBLAs) for Merck's (MRK) Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph), each in combination with Pfizer's (PFE) PADCEV (enfortumab vedotin-ejfv). This combination is proposed for the treatment of patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of April 7, 2026.
This significant development is based on data from the Phase 3 KEYNOTE-905 trial (also known as EV-303), conducted in collaboration with Astellas. Results from the trial demonstrated a statistically significant and clinically meaningful improvement, reducing the risk of event-free survival (EFS) events by 60% and the risk of death by 50% when compared to surgery alone. Furthermore, the pathologic complete response (pCR) rate saw an estimated increase of 48.3 percentage points, rising from 8.6% with surgery alone to 57.1% with the perioperative combination therapy. If approved, this combination would represent the first and only perioperative regimen to have improved survival in this specific patient population, addressing a critical unmet medical need for those ineligible for cisplatin-containing chemotherapy.
Ukraine Engages in Diplomatic Efforts Over US Peace Proposal
Ukrainian President Volodymyr Zelenskyy held discussions with NATO Secretary General Mark Rutte regarding a US peace proposal and available diplomatic options for ending the conflict in Ukraine. Zelenskyy's office confirmed that Ukraine has officially received a draft peace plan from the American side, which the US believes can intensify diplomatic efforts.
The proposed 28-point plan, reportedly drafted by US and Russian officials with the backing of former US President Donald Trump, is said to include "painful concessions" from Ukraine. These concessions reportedly involve recognizing Russian control over territories such as Crimea, Luhansk, and Donetsk, as well as limiting the size of Ukraine's military to 600,000 troops and abandoning aspirations for NATO membership. The plan also suggests the reintegration of Russia into the global economy, with sanctions being lifted in phases.
President Zelenskyy has emphasized Ukraine's readiness for constructive work on the plan but reiterated the importance of achieving a "dignified peace" that respects Ukraine's independence and sovereignty. He is expected to discuss the details of the plan directly with President Trump in the coming days. NATO Secretary General Rutte acknowledged the complexity of these discussions but expressed support for efforts towards peace.
LiveSquawk Delivers Weekly Market Insights
LiveSquawk released its Market Talk Weekly Review, providing its audience with a breakdown of the key financial stories from the past week and their potential implications for global markets. The review also offers a forward-looking perspective on upcoming economic events. While specific details from this particular review were not immediately available, LiveSquawk's weekly analyses typically cover significant market trends, central bank decisions, and global economic data. Older reviews have highlighted topics such as US CPI data and German investor sentiment, indicating the breadth of their market coverage.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.